Coming Down the Pike - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Coming Down the Pike

Coming Down the Pike: Treating Epilepsy

March 2, 2009

Pharmaceutical Technology

Scientists studying epilepsy have traditionally focused on the comings and goings of ions through molecular channels in nerve cells, and many current antiseizure therapies seek to modulate that dynamic.

Coming Down the Pike: Chaperones

November 2, 2008

Pharmaceutical Technology

Molecules called "chaperones" facilitate correct protein folding.

Coming Down the Pike: Protein-Substrate Binding

July 2, 2008

Pharmaceutical Technology

Drugmakers seeking to block the activity of a protein may have a new strategy at their disposal.

Coming Down the Pike: Endocannabinoids

June 2, 2008

Pharmaceutical Technology

Scientists are uncovering signaling systems that operate via cannabinoid messenger molecules.

Coming Down the Pike: Bispecific mABs

April 2, 2008

Pharmaceutical Technology

Antibodies are highly specific molecules that can be tailored to recognize almost any stretch of peptide that nature can conjure: a feature that has been exploited for years now to produce therapeutic antibodies.

Coming Down the Pike: HDAC inhibitors

March 2, 2008

Pharmaceutical Technology

New research and ideas for March 2008

Coming Down the Pike: Sirtuins

February 2, 2008

Pharmaceutical Technology

Text sirtuins are the new kinases, according to a presentation given last month at the JP Healthcare Investors Conference in San Francisco by Sirtis CEO Christoph Westphal.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here